Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq:
MKD), a leading technology-driven platform in China’s chemical
industry, today announced its unaudited financial results for the
fourth quarter and fiscal year ended December 31, 2019.
Fourth Quarter and Fiscal Year 2019
Financial Highlights
- Net revenues in the fourth quarter
of 2019 were RMB4,101.2 million (US$589.1 million), a 38.1%
increase from RMB2,969.6 million in the fourth quarter of 2018. Net
revenues in fiscal year 2019 were RMB13.2 billion (US$1,902.6
million), a 46.3% increase from RMB9.1 billion in fiscal year
2018.
- Gross profit in the fourth quarter
of 2019 was RMB37.4 million (US$5.4 million), a 10.8% increase from
RMB33.7 million in the fourth quarter of 2018. Gross profit in
fiscal year 2019 was RMB103.0 million (US$14.8 million), a 28.5%
increase from RMB80.2 million in fiscal year 2018.
- Net loss in the fourth quarter of
2019 was RMB58.1 million (US$8.3 million), compared with RMB166.6
million in the fourth quarter of 2018. Net loss in fiscal year 2019
was RMB191.3 million (US$27.5 million), compared with RMB254.6
million in fiscal year 2018.
Fourth Quarter and Fiscal Year
2019 Operational Updates
- GMV1 under direct sales model in
the fourth quarter of 2019 was RMB4,069.9 million, a 37.3% increase
from RMB2,964.6 million in the fourth quarter of 2018. GMV under
direct sales model in fiscal year 2019 was RMB13.2 billion, a 45.9%
increase from RMB9.0 billion in fiscal year 2018.
- GMV under marketplace model in the
fourth quarter of 2019 was RMB65.1 billion, a 63.6% increase from
RMB39.8 billion in the fourth quarter of 2018. GMV under
marketplace model in fiscal year 2019 was RMB241.9 billion, a 50.5%
increase from RMB160.7 billion in fiscal year 2018.
- Total GMV under direct sales and
marketplace models in the fourth quarter of 2019 was RMB69.2
billion (US$9.9 billion), a 61.7% increase from RMB42.8 billion in
the fourth quarter of 2018. Total GMV under direct sales and
marketplace models in fiscal year 2019 was RMB255.1 billion
(US$36.4 billion), a 50.3% increase from RMB169.7 billion in fiscal
year 2018.
- As of December 31, 2019, the
Company had accumulated 11,745 customers and 6,253 suppliers on the
Company’s online platform under direct sales model, compared with
9,007 customers and 5,163 suppliers as of December 31, 2018.
- As of December 31, 2019, the
Company had accumulated 110,565 customers and 32,836 suppliers on
the Company’s online platform under marketplace model, compared
with 90,129 customers and 32,011 suppliers as of December 31,
2018.
- As of December 31, 2019, the
Company had over 229,980 users and accumulated a total number of
116,291 customers and 35,456 suppliers on the Company’s online
platform under direct sales and marketplace models, compared with
178,220 users, 94,373 customers and 33,752 suppliers as of December
31, 2018.
______________1 “GMV” refers to gross
merchandise value of the transaction orders placed by customers
under the direct sales model or the gross merchandise value of the
transaction orders the Company facilitates between customers and
suppliers under the marketplace model during the specified period;
under the direct sales model, the GMV does not include discounts or
returns by the customers and may include the shipping fees in some
cases; under the marketplace model, the GMV does not include
shipping fees or discounts, regardless of whether the chemicals are
actually delivered or returned.
Management Comments
“2019 was a landmark year for us, highlighted by
our IPO on the Nasdaq Stock Market, on December 30, 2019, which
created immediate and increased brand awareness to new users,
customers and partners,” said Dr. Dongliang Chang, Founder of the
Company and Chairman of the Board. “We finished 2019 strong with a
number of operational and financial achievements across the board.
To continue our growth momentum in 2020, our strategies focus on
expanding our user base, strengthening customer engagement and
retention, as well as further observing and meeting our customers’
evolving and diverse needs along the entire chemical value
chain.”
“We are pleased to see solid progress with
growth across each of our core business segments in 2019. It is
worth noting that net revenues from our marketplace model and
online membership service both achieved three-digit year-over-year
growth,” commented Dr. Zheng Wang, Chief Executive Officer and
Director of the Company. “With the increasing need of chemical
industry participants to improve their operational efficiencies,
the steady growth of the chemical industry, and an increasing
internet penetration of the chemical e-commerce market, we believe
our comprehensive and sophisticated chemical knowledge engine and
business intelligence capabilities, our one-stop comprehensive
suite of services, and our innovative big data and AI technologies,
place us in an ideal position to further our leadership position in
the sector. As we move through 2020, we will continue to invest in
our knowledge engine and other technologies while looking forward
to further growing our GMV, diversifying our value-added services
and expanding global presence.
“With respect to the COVID-19 pandemic, since
its outbreak, many business operations in China were halted and
factories were temporarily closed for a period of time, which would
negatively affect our overall financial results in the first
quarter of 2020. Depending on the global progression of the
outbreak, our ability to obtain chemicals and deliver chemicals to
customers may be partly or completely disrupted not only in our
Chinese facilities but globally. However, at the same time, we
observed increased online traffic on our platform in early 2020
during the outbreak, compared to the same period in 2019,
especially from overseas customers and suppliers, which is also in
line with our business strategy this year. We are also actively
promoting our financial services to customers and suppliers on our
platform to address potential financial needs during the outbreak.
We believe that we can effectively cope with the dynamics caused by
the outbreak and will continue to closely monitor the evolving
situation,” Dr. Wang concluded.
“We are pleased with our strong financial
results for both the fourth quarter and fiscal year 2019, achieving
outstanding revenue growth while narrowing net loss. Our balance
sheet has also been maintained at a healthy level,” said Mr.
Zhaohong Li, Chief Financial Officer of the Company. “With a goal
to extend our solid growth trend in 2020, we look forward to
further improving our results of operation with an emphasis on
margin expansion and operational efficiencies improvement.”
Fourth Quarter 2019 Financial
Results
Net Revenues
Net revenues were RMB4,101.2 million (US$589.1
million), a 38.1% increase from RMB2,969.6 million in the same
period of 2018. The increase was primarily attributable to the
steady increase in the number of users on the platform.
- Net revenues from direct
sales model were RMB4,079.9 million (US$586.0 million), a
37.6% increase from RMB2,964.6 million in the same period of
2018.
- Net revenues from
marketplace model were RMB15.6 million (US$2.2 million), a
376.9% increase from RMB3.3 million in the same period of 2018.
- Net revenues from online
membership service were RMB3.7 million (US$0.5 million), a
113.2% increase from RMB1.8 million in the same period of 2018.
- Net revenues from financial
service were RMB0.5 million (US$0.07 million), compared
with nil in the same period of 2018.
Cost of Revenues
Cost of revenues was RMB4,063.8 million
(US$583.7 million), a 38.4% increase from RMB2,935.9 million in the
same period of 2018. This change was primarily due to the increase
in net revenues.
Gross Profit and Gross
Margin
Gross profit was RMB37.4 million (US$5.4
million), a 10.8% increase from RMB33.7 million in the same period
of 2018. Gross margin decreased to 0.9%, compared with 1.1% in the
same period of 2018. The decrease in gross margin was primarily due
to a larger amount of basic chemicals that were procured by new
users on the platform which have relatively lower gross margin.
Operating Expenses
Total operating expenses were RMB93.7 million
(US$13.5 million), a 52.5% decrease from RMB197.5 million in the
same period of 2018. The decrease was primarily due to the
reduction of expenses associated with share-based compensation in
the fourth quarter of 2019 compared to the same period in 2018.
- Sales and marketing
expenses were RMB25.7 million (US$3.7 million), a 48.9%
decrease from RMB50.3 million in the same period of 2018. This was
primarily due to decreased share-based compensation for marketing
personnel.
- General and administrative
expenses were RMB26.4 million (US$3.8 million), an 80.2%
decrease from RMB133.1 million in the same period of 2018. This was
primarily due to improved operational efficiencies and decreased
share-based compensation for administrative personnel.
- Research and development
expenses were RMB14.5 million (US$2.1 million), a 15.3%
decrease from RMB17.2 million in the same period of 2018. This was
primarily due to decreased share-based compensation for R&D
personnel.
Operating Loss
Operating loss was RMB56.4 million (US$8.1
million), compared with RMB163.8 million in the same period of
2018.
Net Loss
Net loss was RMB58.1 million (US$8.3 million),
compared with RMB166.6 million in the same period of 2018.
Fiscal Year 2019 Financial
Results
Net Revenues
Net revenues were RMB13.2 billion (US$1,902.6
million), a 46.3% increase from RMB9.1 billion in fiscal year 2018.
The increase was primarily attributable to the Company’s efforts to
diversify product offerings and an increase in overall GMV.
- Net revenues from direct
sales model were RMB13.2 billion (US$1,897.0 million), a
46.0% increase from RMB9.0 billion in fiscal year 2018. The
increase was primarily attributable to an increase in total number
of users and customers, an increase in overall GMV, and the
expansion of chemical product categories and value-added
services.
- Net revenues from
marketplace model were RMB26.5 million (US$3.8 million), a
504.4% increase from RMB4.4 million in fiscal year 2018. The
increase was primarily attributable to the increased customer
engagement on the platform and the Company’s efforts to provide
more value-added services to the customers.
- Net revenues from online
membership service were RMB10.7 million (US$1.5 million),
a 211.3% increase from RMB3.4 million in fiscal year 2018. The
increase was primarily attributable to the increased number of
users signing up for the online membership services.
- Net revenues from financial
service were RMB0.9 million (US$0.1 million), compared
with nil in fiscal year 2018, as the Company commenced monetizing
on financial service in July 2019.
Cost of Revenues
Cost of revenues was RMB13.1 billion (US$1,887.8
million), a 46.5% increase from RMB9.0 billion in fiscal year 2018.
This change was primarily due to the increase in the purchase
volume of chemicals, which was in line with the net revenues
growth.
Gross Profit and Gross
Margin
Gross profit was RMB103.0 million (US$14.8
million), a 28.5% increase from RMB80.2 million in fiscal year
2018. Gross margin decreased to 0.8%, compared with 0.9% in fiscal
year 2018. The slight decrease in gross margin was primarily due to
a larger amount of basic chemicals that were procured by new users
on the platform which have relatively lower gross margin.
Operating Expenses
Total operating expenses were RMB293.0 million
(US$42.1 million), a 7.3% decrease from RMB316.0 million in fiscal
year 2018.
- Sales and marketing
expenses were RMB108.9 million (US$15.6 million), a 5.4%
increase from RMB103.3 million in fiscal year 2018.
- General and administrative
expenses were RMB104.5 million (US$15.0 million), a 39.9%
decrease from RMB173.9 million in fiscal year 2018. This was
primarily due to improved operational efficiencies and decreased
share-based compensation for administrative personnel.
- Research and development
expenses were RMB45.0 million (US$6.5 million), a 22.1%
increase from RMB36.9 million in fiscal year 2018. This was
primarily due to the constant increase of R&D investments.
Operating Loss
Operating loss was RMB190.0 million (US$27.3
million), compared with RMB235.8 million in fiscal year 2018.
Net Loss
Net loss was RMB191.3 million (US$27.5 million),
compared with RMB254.6 million in fiscal year 2018.
Certain Balance Sheet Item
As of December 31, 2019, the Company had cash,
cash equivalents and restricted cash of RMB57.7 million (US$8.3
million), compared to RMB6.5 million as of December 31, 2018.
Conference Call
The Company’s management will host an earnings
conference call at 8:00 PM U.S. Eastern Time on March 25, 2020
(8:00 AM Beijing/Hong Kong time on March 26, 2020).
Dial-in details for the earnings conference call
are as follows:
United States: |
+1-866-519-4004 |
International: |
+65-6713-5090 |
Hong Kong: |
800-906-601 |
Mainland China: |
400-620-8038 |
Conference ID: |
6679446 |
A telephone replay will be available two hours
after the call until April 8, 2020 by dialing:
United States: |
+1-855-452-5696 |
International: |
+61-2-8199-0299 |
Replay Access Code: |
6679446 |
Additionally, a live and archived webcast of the
conference call will be available on the Company’s investor
relations website at http://investor.molbase.com/.
About Molecular Data Inc.
Molecular Data Inc. is a leading
technology-driven platform in China’s chemical industry, connecting
participants along the chemical value chain through integrated
solutions. The Company delivers e-commerce solutions, financial
solutions, warehousing and logistics solutions, and SaaS suite that
are intended to solve pain points for participants in the
traditional chemical industry. Built upon a comprehensive knowledge
engine and artificial intelligence (AI) capabilities, the Company’s
e-commerce solutions are mainly offered through its online
platform, consisting of molbase.com, molbase.cn, Moku Data Weixin
account, Chemical Community App and other ancillary platforms.
Exchange Rate Information
This announcement contains translations of
certain RMB amounts into U.S. dollars at a specified rate solely
for the convenience of the reader. Unless otherwise noted, all
translations from RMB to U.S. dollars are made at a rate of
RMB6.9618 to US$1.00, the rate in effect as of December 31, 2019
published by the Federal Reserve Board.
Safe Harbor Statement
This announcement contains forward-looking
statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as “will,” “expects,” “anticipates,” “aims,”
“future,” “intends,” “plans,” “believes,” “estimates,” “confident,”
“potential,” “continue” or other similar expressions. Among other
things, the Outlook and quotations from management in this
announcement, as well as the Company’s strategic and operational
plans, contain forward-looking statements. The Company may also
make written or oral forward-looking statements in its periodic
reports to the U.S. Securities and Exchange Commission, in its
annual report to shareholders, in press releases and other written
materials and in oral statements made by its officers, directors or
employees to third parties. Statements that are not historical
facts, including but not limited to statements about the Company’s
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties, and a variety of factors could cause actual results
to differ materially from those contained in any forward-looking
statement, including but not limited to the following: the
Company’s goals and strategies; the Company’s future business
development, results of operations and financial condition; the
expected growth of the education market; the Company’s ability to
monetize the user base; fluctuations in general economic and
business conditions in China; the potential impact of the COVID-19
to the Company’s business operations and the economy in China and
elsewhere generally; and assumptions underlying or related to any
of the foregoing. Further information regarding these and other
risks is included in the Company’s filings with the Securities and
Exchange Commission. All information provided in this press release
and in the attachments is as of the date of the press release, and
the Company undertakes no duty to update such information, except
as required under applicable law.
For investor and media inquiries, please
contact:
In China:
Molecular Data Inc.Eva MaTel: +86-400-6021-666E-mail:
investor@molbase.com
The Piacente Group, Inc.Emilie WuTel: +86-21-6039-8363E-mail:
molbase@tpg-ir.com
In the United States:
The Piacente Group, Inc. Brandi PiacenteTel:
+1-212-481-2050E-mail: molbase@tpg-ir.com
Source: Molbase
|
MOLECULAR DATA
INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE
SHEETS(Amounts in thousands of RMB and
US$) |
|
|
|
As of December 31, |
|
|
|
2018 |
|
2019 |
|
|
|
(RMB’000) |
|
(RMB’000) |
|
(USD’000) |
|
|
|
|
|
|
Unaudited |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash
equivalents |
|
6,477 |
|
|
5,156 |
|
|
741 |
|
|
Restricted cash |
|
- |
|
|
52,518 |
|
|
7,544 |
|
|
Accounts receivable, net |
|
40,730 |
|
|
20,424 |
|
|
2,934 |
|
|
Unbilled receivables |
|
12,813 |
|
|
106,060 |
|
|
15,235 |
|
|
Notes receivable |
|
2,075 |
|
|
124,176 |
|
|
17,837 |
|
|
Inventories, net |
|
7,256 |
|
|
4,351 |
|
|
625 |
|
|
Amounts due from related parties |
|
2,366 |
|
|
828 |
|
|
119 |
|
|
Prepayments and other current assets |
|
295,985 |
|
|
215,125 |
|
|
30,900 |
|
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
367,702 |
|
|
528,638 |
|
|
75,935 |
|
|
|
|
|
|
|
|
|
|
|
Non-current assets: |
|
|
|
|
|
|
|
|
Property and equipment, net |
|
1,762 |
|
|
1,106 |
|
|
159 |
|
|
Intangible assets, net |
|
2,134 |
|
|
1,560 |
|
|
224 |
|
|
Operating lease right-of-use assets |
|
- |
|
|
3,219 |
|
|
462 |
|
|
|
|
|
|
|
|
|
|
|
Total non-current assets |
|
3,896 |
|
|
5,885 |
|
|
845 |
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
371,598 |
|
|
534,523 |
|
|
76,780 |
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders’ Deficit |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Short-term borrowings |
|
82 |
|
|
13,749 |
|
|
1,975 |
|
|
Accounts payable |
|
49,315 |
|
|
338,941 |
|
|
48,686 |
|
|
Deferred revenue |
|
153,467 |
|
|
107,181 |
|
|
15,396 |
|
|
Accrued expenses and other liabilities |
|
24,709 |
|
|
108,034 |
|
|
15,518 |
|
|
Operating lease liabilities-current |
|
- |
|
|
3,080 |
|
|
442 |
|
|
Amount due to related parties-current |
|
27,844 |
|
|
143,958 |
|
|
20,678 |
|
|
Income taxes payable |
|
- |
|
|
352 |
|
|
51 |
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
255,417 |
|
|
715,295 |
|
|
102,746 |
|
|
|
|
|
|
|
|
|
|
|
Non-current liabilities: |
|
|
|
|
|
|
|
|
Amounts due to related parties-non-current |
|
177,776 |
|
|
33,453 |
|
|
4,805 |
|
|
Deferred government grants |
|
30 |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
Total non-current liabilities |
|
177,806 |
|
|
33,453 |
|
|
4,805 |
|
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
433,223 |
|
|
748,748 |
|
|
107,551 |
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ deficit |
|
|
|
|
|
|
|
|
Ordinary shares |
|
98 |
|
|
98 |
|
|
14 |
|
|
Additional paid-in capital |
|
498,626 |
|
|
537,618 |
|
|
77,223 |
|
|
Accumulated other comprehensive loss |
|
- |
|
|
(316 |
) |
|
(45 |
) |
|
Accumulated deficits |
|
(560,349 |
) |
|
(751,625 |
) |
|
(107,963 |
) |
|
|
|
|
|
|
|
|
|
|
Total shareholders’ deficit |
|
(61,625 |
) |
|
(214,225 |
) |
|
(30,771 |
) |
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders'
deficit |
|
371,598 |
|
|
534,523 |
|
|
76,780 |
|
|
|
MOLECULAR
DATA INC.UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF INCOME(Amounts in thousands of RMB
and US$, except for number of shares and per share
data) |
|
|
Quarter Ended |
|
Year Ended |
|
December 31,
2018 |
December 31,
2019 |
December 31,
2019 |
|
December 31,
2018 |
December 31,
2019 |
December 31
2019 |
|
(RMB'000) |
(RMB'000) |
(USD'000) |
|
(RMB'000) |
(RMB'000) |
(USD'000) |
|
Unaudited |
|
|
Unaudited |
|
|
|
|
|
|
|
|
Total
net revenues |
2,969,580 |
|
4,101,200 |
|
589,101 |
|
|
9,053,266 |
|
13,245,839 |
|
1,902,646 |
|
Chemical Trading – direct sales model |
2,964,556 |
|
4,079,854 |
|
586,035 |
|
|
9,045,458 |
|
13,206,243 |
|
1,896,958 |
|
Chemical Trading – marketplace model |
3,270 |
|
15,596 |
|
2,240 |
|
|
4,387 |
|
26,513 |
|
3,808 |
|
Online membership service |
1,754 |
|
3,740 |
|
537 |
|
|
3,421 |
|
10,650 |
|
1,530 |
|
Financial service |
- |
|
494 |
|
71 |
|
|
- |
|
917 |
|
132 |
|
Others |
- |
|
1,516 |
|
218 |
|
|
- |
|
1,516 |
|
218 |
|
Cost of revenues |
(2,935,863 |
) |
(4,063,842 |
) |
(583,734 |
) |
|
(8,973,097 |
) |
(13,142,828 |
) |
(1,887,849 |
) |
|
|
|
|
|
|
|
|
Gross profit |
33,717 |
|
37,358 |
|
5,367 |
|
|
80,169 |
|
103,011 |
|
14,797 |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
Sales and marketing expenses |
(50,280 |
) |
(25,689 |
) |
(3,690 |
) |
|
(103,293 |
) |
(108,858 |
) |
(15,636 |
) |
General and administrative expenses |
(133,079 |
) |
(26,354 |
) |
(3,786 |
) |
|
(173,872 |
) |
(104,471 |
) |
(15,006 |
) |
Research and development expenses |
(17,159 |
) |
(14,535 |
) |
(2,088 |
) |
|
(36,889 |
) |
(45,038 |
) |
(6,469 |
) |
Reversal/(Allowance) for doubtful accounts |
3,036 |
|
(27,137 |
) |
(3,898 |
) |
|
(1,907 |
) |
(34,618 |
) |
(4,973 |
) |
Total operating expenses |
(197,482 |
) |
(93,715 |
) |
(13,462 |
) |
|
(315,961 |
) |
(292,985 |
) |
(42,084 |
) |
|
|
|
|
|
|
|
|
Operating loss |
(163,765 |
) |
(56,357 |
) |
(8,095 |
) |
|
(235,792 |
) |
(189,974 |
) |
(27,287 |
) |
|
|
|
|
|
|
|
|
Interest expenses, net |
(3,942 |
) |
(2,193 |
) |
(315 |
) |
|
(19,049 |
) |
(4,368 |
) |
(627 |
) |
Foreign exchange (loss)/gain |
(9 |
) |
12 |
|
2 |
|
|
(3,033 |
) |
185 |
|
27 |
|
Other income, net |
838 |
|
914 |
|
132 |
|
|
3,235 |
|
3,311 |
|
475 |
|
|
|
|
|
|
|
|
|
Loss before income tax |
(166,878 |
) |
(57,624 |
) |
(8,276 |
) |
|
(254,639 |
) |
(190,846 |
) |
(27,412 |
) |
|
|
|
|
|
|
|
|
Income tax benefits/(expenses) |
277 |
|
(430 |
) |
(62 |
) |
|
- |
|
(430 |
) |
(62 |
) |
|
|
|
|
|
|
|
|
Net loss |
(166,601 |
) |
(58,054 |
) |
(8,338 |
) |
|
(254,639 |
) |
(191,276 |
) |
(27,474 |
) |
|
|
|
|
|
|
|
|
Net loss attributable to Molecular Data
Inc. |
(166,601 |
) |
(58,054 |
) |
(8,338 |
) |
|
(254,639 |
) |
(191,276 |
) |
(27,474 |
) |
|
|
|
|
|
|
|
|
Loss per share: |
|
|
|
|
|
|
|
Basic and diluted |
(0.54 |
) |
(0.19 |
) |
(0.03 |
) |
|
(0.82 |
) |
(0.62 |
) |
(0.09 |
) |
|
|
|
|
|
|
|
|
Weighted average shares
outstanding |
|
|
|
|
|
|
Basic and diluted |
310,627,024 |
|
310,627,024 |
|
310,627,024 |
|
|
310,627,024 |
|
310,627,024 |
|
310,627,024 |
|
|
|
|
|
|
|
|
|
Other comprehensive income, net of tax of
nil |
- |
|
- |
|
- |
|
|
- |
|
- |
|
- |
|
Comprehensive loss |
(166,601 |
) |
(58,054 |
) |
(8,338 |
) |
|
(254,639 |
) |
(191,276 |
) |
(27,474 |
) |
Comprehensive loss attributable to Molecular Data
Inc. |
(166,601 |
) |
(58,054 |
) |
(8,338 |
) |
|
(254,639 |
) |
(191,276 |
) |
(27,474 |
) |
Molecular Data (NASDAQ:MKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Data (NASDAQ:MKD)
Historical Stock Chart
From Jul 2023 to Jul 2024